Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

TLR9 triggering in Burkitt's lymphoma cell lines suppresses the EBV BZLF1 transcription via histone modification.

Zauner L, Melroe GT, Sigrist JA, Rechsteiner MP, Dorner M, Arnold M, Berger C, Bernasconi M, Schaefer BW, Speck RF, Nadal D.

Oncogene. 2010 Aug 12;29(32):4588-98. doi: 10.1038/onc.2010.203. Epub 2010 May 31.

PMID:
20514021
2.

IRAK4 is essential for TLR9-induced suppression of Epstein-Barr virus BZLF1 transcription in Akata Burkitt's lymphoma cells.

Jordi M, Marty J, Mordasini V, Lünemann A, McComb S, Bernasconi M, Nadal D.

PLoS One. 2017 Oct 31;12(10):e0186614. doi: 10.1371/journal.pone.0186614. eCollection 2017.

3.

A molecular link between malaria and Epstein-Barr virus reactivation.

Chêne A, Donati D, Guerreiro-Cacais AO, Levitsky V, Chen Q, Falk KI, Orem J, Kironde F, Wahlgren M, Bejarano MT.

PLoS Pathog. 2007 Jun;3(6):e80.

4.

Immune activation suppresses initiation of lytic Epstein-Barr virus infection.

Ladell K, Dorner M, Zauner L, Berger C, Zucol F, Bernasconi M, Niggli FK, Speck RF, Nadal D.

Cell Microbiol. 2007 Aug;9(8):2055-69. Epub 2007 Apr 5.

PMID:
17419714
5.

TLR9 agonists induced cell death in Burkitt's lymphoma cells is variable and influenced by TLR9 polymorphism.

Noack J, Jordi M, Zauner L, Alessi D, Burch A, Tinguely M, Hersberger M, Bernasconi M, Nadal D.

Cell Death Dis. 2012 Jun 21;3:e323. doi: 10.1038/cddis.2012.60.

6.

Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.

Niedobitek G, Agathanggelou A, Rowe M, Jones EL, Jones DB, Turyaguma P, Oryema J, Wright DH, Young LS.

Blood. 1995 Jul 15;86(2):659-65.

7.

Induction of Epstein-Barr virus (EBV) reactivation in Raji cells by doxorubicin and cisplatin.

Hsu CH, Hergenhahn M, Chuang SE, Yeh PY, Wu TC, Gao M, Cheng AL.

Anticancer Res. 2002 Nov-Dec;22(6C):4065-71.

PMID:
12553034
8.

hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies.

Giunco S, Dolcetti R, Keppel S, Celeghin A, Indraccolo S, Dal Col J, Mastorci K, De Rossi A.

Clin Cancer Res. 2013 Apr 15;19(8):2036-47. doi: 10.1158/1078-0432.CCR-12-2537. Epub 2013 Feb 26.

9.

Endemic Burkitt's lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virus.

Chene A, Donati D, Orem J, Mbidde ER, Kironde F, Wahlgren M, Bejarano MT.

Semin Cancer Biol. 2009 Dec;19(6):411-20. doi: 10.1016/j.semcancer.2009.10.002. Epub 2009 Nov 6. Review.

PMID:
19897039
10.

The 5' regulatory sequences of active miR-146a promoters are hypomethylated and associated with euchromatic histone modification marks in B lymphoid cells.

Szenthe K, Koroknai A, Banati F, Bathori Z, Lozsa R, Burgyan J, Wolf H, Salamon D, Nagy K, Niller HH, Minarovits J.

Biochem Biophys Res Commun. 2013 Apr 19;433(4):489-95. doi: 10.1016/j.bbrc.2013.03.022. Epub 2013 Mar 23.

PMID:
23528241
11.

Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines.

Weber-Nordt RM, Egen C, Wehinger J, Ludwig W, Gouilleux-Gruart V, Mertelsmann R, Finke J.

Blood. 1996 Aug 1;88(3):809-16.

12.

Regulation of interleukin-1beta transcription by Epstein-Barr virus involves a number of latent proteins via their interaction with RBP.

Krauer KG, Belzer DK, Liaskou D, Buck M, Cross S, Honjo T, Sculley T.

Virology. 1998 Dec 20;252(2):418-30.

13.

[Effects of Epstein-Barr virus on host gene expression in Burkitt's lymphoma cell lines].

Broderick P, Hubank M, Sinclair A.

Ai Zheng. 2009 Aug;28(8):813-21. Chinese.

PMID:
19664326
14.
15.

Latent membrane protein 1 is critical for efficient growth transformation of human B cells by epstein-barr virus.

Dirmeier U, Neuhierl B, Kilger E, Reisbach G, Sandberg ML, Hammerschmidt W.

Cancer Res. 2003 Jun 1;63(11):2982-9.

16.

CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease.

Robertson KD, Manns A, Swinnen LJ, Zong JC, Gulley ML, Ambinder RF.

Blood. 1996 Oct 15;88(8):3129-36.

17.

Expression of Epstein-Barr virus-gene products in Burkitt's lymphoma in Northeast Brazil.

Araujo I, Foss HD, Bittencourt A, Hummel M, Demel G, Mendonca N, Herbst H, Stein H.

Blood. 1996 Jun 15;87(12):5279-86.

19.

EBV lytic-phase protein BGLF5 contributes to TLR9 downregulation during productive infection.

van Gent M, Griffin BD, Berkhoff EG, van Leeuwen D, Boer IG, Buisson M, Hartgers FC, Burmeister WP, Wiertz EJ, Ressing ME.

J Immunol. 2011 Feb 1;186(3):1694-702. doi: 10.4049/jimmunol.0903120. Epub 2010 Dec 29.

20.

Expression of recombination activating genes (RAG-1 and RAG-2) in Epstein-Barr virus-bearing B cells.

Kuhn-Hallek I, Sage DR, Stein L, Groelle H, Fingeroth JD.

Blood. 1995 Mar 1;85(5):1289-99.

Supplemental Content

Support Center